Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Aurinia Pharmaceuticals Inc (AUPH) Gets the Thumbs Up From Cantor

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is in the spotlight on Monday after Cantor Fitzgerald initiated an ‘Overweight’ rating and a target of $14 per share. Cantor analyst Elemer Piros is bullish on the name due to his belief that Aurinia’s lead drug candidate, voclosporin, has shown ‘compelling efficacy’ (in his view) in the Phase 2 study, AURA-LV. Dr. Piros believes the commercial market opportunity could be as much as $1.6 billion in just the United States.

After surging sharply in early March, volatility surrounding Aurinia has inched lower as traders have digested much of the present news. Some traders believe shares of the Aurinia could be in focus later on this month, when the company hosts an Investor Event during the National Kidney Foundation Spring Clinical Meeting on April 20, 2017 at 6:00pm Eastern Time. The event is intended for sell-side analysts, investors, and business development professionals.

What Does The Smart Money Sentiment Say?

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

Given that it’s a small company, none of the 742 elite funds in our database owned Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) at the end of Q4. That metric might change going forward, however.

The Bottom Line

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are in the spotlight today after Cantor Fitzgerald gave the thumbs up to the stock. For more reading, check out ‘11 Biggest Generic Drug Companies In the World‘.

Follow Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Trade (NASDAQ:AUPH) Now!


U.S. Financial Hub: Wall Street

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.